The Met pathway: Master switch and drug target in cancer progression

FASEB Journal

Volumn 20, Issue 10, 2006, Pages 1611-1621

  Mazzone, Massimiliano ^a,b   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Crosstalk; HGF; Inhibitors; Invasive growth; Microenvironment

Indexed keywords

AE 941; BEVACIZUMAB; COMBRETASTATIN; CYTOKINE; EPHRIN; EPHRIN A1; EPHRIN B1; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; GEFITINIB; GROWTH FACTOR; IMATINIB; METHIONINE; SEMAXANIB; SOMATOMEDIN; TRASTUZUMAB; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN;

CANCER GROWTH; CELL GROWTH; CELL MOTILITY; DRUG TARGETING; GENE MUTATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; CANCER INVASION; DISEASE COURSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM; NEOPLASM;

DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR;

EID: 33749367676     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-5947rev     Document Type: Review

References (124)

1. Chambers, A. F., Groom, A. C., and MacDonald, I. C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572
2. Vogelstein, B., and Krinzler, K. W. (2004) Cancer genes and pathways they control. Nat. Med. 10, 789-799
3. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70
4. Steeg, P. S. (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 3, 55-63
5. Trusolino, L., and Comoglio, P. M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289-300
6. Comoglio, P. M., and Boccaccio, C. (2001) Scatter factor and invasive growth. Semin. Cancer Biol. 11, 153-165
7. Nieto, M. A. (2001) The early steps of neural crest development. Mech. Dev. 105, 27-35
8. Shook, D., and Keller, R. (2003) Mechanisms, mechanics and function or epithelial-mesenchymal transitions in early development. Mech. Dev. 120, 1351-1383
9. Thiery, J. P. (2002) Epithelial mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454
10. Kang, Y., and Massague, J. (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279
11. Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R. A. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939
12. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744-749
13. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., and Kirchner, T. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U. S. A. 98, 10356-10361
14. Barker, N., and Clevers, H. (2001) Tumor environment: a potent driving force in colorectal cancer? Trends Mol. Med. 7, 535-537
15. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., and Shimizu, S. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443
16. Skeel, A., Yoshimura, T., Showalter, S. D., Skeel, A., Yoshimura, T., and Showalter, S. D. (1991) Macrophage stimulation protein: purification, partial amino acid sequence, and cellular activity. J. Exp. Med. 173, 1227-1234
17. Stoker, M., Gherardi, E., Perryman, M., and Gray, J. (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242
18. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R. P., Hartmann, G., Zarnegar, R., Michalopoulos, G.K., Birchmeier, W., and Comoglio, P. M. (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867-2878
19. Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S., and Comoglio, P. M. (1989) Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155-156
20. Birchmeier, C., and Gherardi, E. (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404-410
21. Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., and Kitamura, N. (1995) Placenta defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705
22. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771
23. Yanagida, H., Kaibori, M., Hijikawa, T., Kwon, A. H., Kamiyama, Y., and Okumura, T. (2006) Administration of rh-HGF-activator via portal vein stimulates the regeneration of cirrhotic liver after partial hepatectomy in rats. J. Surg. Res. 130, 38-44
24. Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., Matsuda, H., and Nakamura, T. (2000) Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519
25. Huh, C. G., Factor, V. M., Sanchez, A., Uchida, K., Conner, E. A., and Thorgeirsson, S. S. (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. 101, 4477-4482
26. Rong, S., Segal, S., Anver, M., Resau, J. H., and Vande Woude, G. F. (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. U. S. A. 91, 4731-4735
27. Michieli, P., Basilico, C., Pennacchietti, S., Maffe, A., Tamagnone, L., Giordano, S., Bardelli, A., and Comoglio, P. M. (1999) Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18, 5221-5231
28. Chiara, F., Michieli, P., Pugliese, L., and Comoglio, P. M. (2003) Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J. Biol. Chem. 278, 29352-29358
29. Boccaccio, C., Sabatino, G., Medico, E., Follenzi, A., Reato, G., Sottile, A., Naldini, L., and Comoglio, P. M. (2005) The MET oncogene drivers a genetic programme linking cancer to haemostasis. Nature 434, 396-400
30. Boccaccio, C., and Comoglio, P. M. (2005) A functional role for hemostasis in early cancer development. Cancer Res. Rev. 65, 8579-82
31. Corso, S., Comoglio, P. M., and Giordano, S. (2005) Cancer therapy: can the challenge be MET? Trends Mol. Med. 11, 284-292
32. Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., Aaronson, S. A., and Merlino, G. (1997) Diverse tumorigenesis associated with aberrant development mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. U. S. A. 94, 701-706
33. Di Renzo, M. F., Olivero, M., Katsaros, D., Crepaldi, T., Gaglia, P., Zola, P., Sismondi, P., and Comoglio, P. M. (1994) Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer 58, 658-662
34. Di Renzo, M. F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., Giordano, S., and Comoglio, P. M. (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147-154
35. Morello, S., Olivero, M., Aimetti, M., Bernardi, M., Berrone, S., Di Renzo M. F., Giordano, S. (2001) MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J. Cell. Physiol. 189, 285-290
36. Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., Vocke, C., Brown, J. A., Jenkins, R., Richard, S., Bergerheim, U., Gerrard, B., Dean, M., Linehan, W. M., and Zbar, B. (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Ocogene 18, 2343-2350
37. Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., Kratzke, R. A., Gordon, G. J., Sugarbaker, D. J., Bueno, R., Janamanchi, V., Bindokas, V. P., Kindler, H. L., and Salgia, R. (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352-361
38. Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., Severin, C., Rangell, L., Schwall, R., Amler, L., Wickramasinghe, D., and Yauch, R. (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-289
39. Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., and Comoglio, P. M. (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547-1555
40. Lorenzato, A., Olivero, M., Patane, S., Rosso, E., Oliaro, A., Comoglio, P. M., and Di Renzo, M. F. (2002) Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62, 7025-7030
41. Cortesina, G., Martone, T., Galeazzi, E., Olivero, M., De Stefani, A., Bussi, M., Valente, G., Comoglio, P. M., and Di Renzo, M. F. (2000) Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int. J. Cancer 89, 286-292
42. Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., and Weissman, I. L. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409-414
43. Polakis, P. (1999) The oncogenic activation of the beta-catenin. Curr. Opin. Genet. Dev. 9, 15-21
44. Kirchner, T., and Brabletz, T. (2000) Pattering and nuclear beta-catenin expression in the coloni adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am. J. Pathol. 157, 1113-1121
45. Boon, E. M., van der Neut, R., van de Wetering, M., Clevers, H., and Pals, S. T. (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62, 5126-5128
46. Monga, S. P., Mars, W. M., Pediaditakis, P., Bell, A., Mule, K., Bowen, W. C., Wang, X., Zarnegar, R., and Michalopoulos, G. K. (2002) Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res. 62, 2064-2071
47. Stella, M. C., Trusolino, L., Pennacchietti, S., and Comoglio, P. M. (2005) Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol. 25, 3982-96
48. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., and Zlotnik, A. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56
49. Tanaka, T., Bai, Z., Srinoulprasert, Y., Yang, B. G., Hayasaka, H., and Miyasaka, M. (2005) Chemokines in tumor progression and metastasis. Cancer Sci. 96, 317-22
50. Paget, S. (1989) The distribution of secondary growths in cancer of the breast 1889. Cancer Metastasis Rev. 8, 98-101
51. Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., and Yamamoto, T. (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544
52. Gabarra-Niecko, V., Schaller, M. D., and Dunty, J. M. (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 22, 359-374
53. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., and Frame, M. C. (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer 5, 505-15
54. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., and Schlaepfer, D. D. (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2, 249-256
55. Guo, W., and Giancotti, F. G. (2004) Integrin signalling during tumour progression. Nat. Rev. Mol. Cell. Biol. 5, 816-826
56. Kajiji, S., and Tamura, R. N. (1989) A novel integrin (alpha E beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors. EMBO J. 8, 673-680
57. Dajee, M., Lazarov, M., Zhang, J.Y., Cai, T., Green, C.L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y., and Khavari, P. A. (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 594-595
58. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., and Mercurio, A. M. (1997) Activation of phosphoinositide3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 91, 949-960
59. De Rooij, J., Kerstens, A., Danuser, G., Schwartz, M. A., and Waterman-Storer, C. M. (2005) Integrin-dependent actomyosin contraction regulates epithelial cell scattering. J. Cell Biol. 171, 153-164
60. Trusolino, L., Bertotti, A., and Comoglio, P. M. (2001) A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654
61. Bertotti, A., Comoglio, P. M., and Trusolino, L. (2005) Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674-10679
62. Bertotti, A., and Comoglio, P. M. (2003) Tyrosine kinase signal specificity: lesson from the HGF receptor. Trends Biochem. Sci. 28, 527-533
63. Boyer, B., Roche, S., Denoyelle, M., and Thiery, J. P. (1997) Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO J. 16, 5904-5913
64. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. (1998) A causal role for E-caderin in the transition from adenoma to carcinoma. Nature 392, 190-193
65. Fujita, Y., Krause, G., Scheffner, M., Zechner, D., Leddy, H. E., Behrens, J., Sommer, T., and Birchmeier, W. (2002) Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 4, 222-231
66. Nieto, M. A. (2002) The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell. Biol. 3, 155-166
67. Novak, A., Hsu, S. C., Leung-Hagesteijn, C., Radeva, G., Papkoff, J., Montesano, R., Roskelley, C., Grosschedl, R., and Dedhar, S. (1998) Cell adhesion the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 95, 4374-4379
68. Cary, L. A., Han, D. C., Polte, T. R., Hanks, S. K., and Guan, J. L. (1998) Identification of p130Cas as a mediator of focal adhesion kinase-promoter cell migration. J. Cell Biol. 140, 211-221
69. Van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) A gene-expression signature as a predictor of survival in breast. N. Engl. J. Med. 347, 1999-2009
70. Ramaswamy, S., Ross, K. N., Lander, E. S., and Golub, T. R. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54
71. Batlle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J., and Garcia DeHerreros, A. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84-89
72. Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., and Nieto, M. A. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83
73. Yang, L. Y., Wang, W., Peng, J. X., Yang, J. Q., and Huang, G. W. (2004) Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. World J. Gastroenterol. 10, 3569-3573
74. Savagner, P., Yamada, K. M., and Thiery, J. P. (1997) The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J. Cell Biol. 137, 1403-1419
75. Gupta, P. B., Kuperwasser, C., Brunet, J. P., Ramaswamy, S., Kuo, W. L., Gray, J. W., Naber, S. P., and Weinberg, R. A. (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047-1054
76. Van't Veer, L. J., Dai, H., Van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536
77. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535
78. Lee, H. O., Leyorse, J. M., and Shin, M. K. (2003) The endothelial receptor-B is required for the migration of neural crest-derived melanocyte and enteric neuron precursors. Dev. Biol. 259, 162-175
79. Britsch, S., Li, L., Kirchhoff, S., Theuring, F., Brinkmann, V., Birchmeier, C., and Riethmacher, D. (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 12, 1825-1836
80. Matsumoto, K., and Nakamura, T. (2006) Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer
81. Bhowmick, N. A., Neilson, E. G., and Moses, H. L. (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337
82. Lewis, C. E., and Pollard, J. W. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res. Rev. 66, 605-12
83. Jain, R. K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62
84. Alitalo, K., Tammela, T., and Petrova, T. V. (2005) Lymphangiogenesis in development and human disease. Nature 438, 946-53
85. Lin, J., Lalani, A. S., Harding, T. C., Gonzalez, M., Wu, W. W., Luan, B., Tu, G. H., Koprivnikar, K., VanRoey, M. J., He, Y., Alitalo, K., and Jooss, K. (2005) Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of soluble VEGFR-3 decoy receptor. Cancer Res. 65, 6901-9
86. Bottaro, D. P., and Liotta, L. A. (2003) Cancer: Out of air is not out of action. Nature 423, 593-595
87. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528
88. Durand, R. E. (1994) The influence of microenvironmental factors during cancer therapy. In Vivo 8, 691-702
89. Pugh, C. W., and Ratcliffe, P. J. (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684
90. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361
91. Adjei, A. A., and Hidalgo, M. (2005) Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 23, 5386-5403
92. Eccles, S. A. (2004) Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int. J. Dev. Biol. 48, 583-598
93. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. (2002) Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov. 1, 415-426
94. Tozer, G. M., Kanthou, C., and Baguley, B. C. (2005) Disrupting tumour blood vessels. Nat. Rev. Cancer 5, 423-435
95. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732
96. Brown, J. M., and Wilson, W. R. (2004) Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447
97. Subarsky, P., and Hill, R. P. (2003) The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20, 237-250
98. Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., Memmert, K., Naegeli, H. U., Petersen, F., Eck, M. J., Bair, K. W., Wood, A. W., and Livingston, D. M. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33-43
99. Yeatman, T. J. (2004) A renaissance for SRC. Nat. Rev. Cancer 4, 470-480
100. Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M. A., Brunton, V. G., and Frame, M. C. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat. Cell Biol. 4, 632-638
101. Golubovskaya, V. M., Gross, S., Kaur, A. S., Wilson, R. I., Xu, L. H., Yang, X. H., and Cance, W. G. (2003) Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol. Cancer Res. 1, 755-764
102. Montemurro, F., Valabrega, G., and Aglietta, M. (2004) Trastuzumab-based combination therapy for breast cancer. Expert Opin. Pharmacother. 5, 81-96
103. Giordano, S., Corso, S., Conrotto, P., Artigiani, S., Gilestro, G., Barberis, D., Tamagnone, L., and Comoglio, P. M. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4, 720-724
104. Follenzi, A., Bakovic, S., Gual, P., Stella, M.C., Longati, P., and Comoglio, P. M. (2000) Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19, 3041-3049
105. Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P., and Ponta, H. (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086
106. Jo, M., Stolz, D.B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., and Strom, S. C. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275, 8806-8811
107. Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R.A., Bell, D. W., Sgroi, D.C., Christensen, J. G., Settleman, J., and Haber, D. A. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U. S. A. 103, 2316-2321
108. Christensen, J. G., Burrows, J., and Salgia, R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225, 1-26
109. Sattler, M., Pride, Y. B., Ma, P., Gramlich, J. L., Chu, S. C., Quinnan, L. A., Shirazian, S., Liang, C., Podar, K., Christensen, J. G., and Salgia, R. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63, 5462-5469
110. Morotti, A., Mila, S., Accornero, P., Tagliabue, E., and Ponzetto, C. (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-4893
111. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., and Mendel, D. B. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345-7355
112. Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L. M., and Vande Woude, G. F. (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U. S. A. 98, 7443-7448
113. Date, K., Matsumoto, K., Kuba, K., Shimura, H., Tanaka, M., and Nakamura, T. (1998) Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 17, 3045-3054
114. Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., Comoglio, P. M., and Michieli, P. (2004) An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 114, 1418-1432
115. Kong-Beltran, M., Stamos, J., and Wickramasinghe, D. (2004) The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6, 75-84
116. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., and Comoglio, P. M. (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73
117. Shinomiya, N., Gao, C. F., Xie, Q., Gustafson, M., Waters, D. J., Zhang, Y. W., and Vande Woude, G. F. (2004) RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res. 64, 7962-7970
118. Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., Comoglio, P. M., and Giordano, S. (2006) Antibody-induced ectodomain shedding mediates HGF receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. U. S. A. In press.
119. Galimi, F., Bagnara, G. P., Bonsi, L., Cottone, E., Follenzi, A., Simeone, A., and Comoglio, P. M. (1994) Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J. Cell Biol. 127, 1743-1754
120. Bissell, M. J., and Radisky, D. (2001) Putting tumors in context. Nat. Rev. Cancer 1, 46-54
121. Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. (1995) Scatter factor/hepatocyte growth is essential for liver development. Nature 373, 699-702
122. Huh, C. G., Factor, V. M., Sanchez, A., Uchida, K., Conner, E. A., and Thorgeirsson, S. S. (2004) Hepatocyte growth factor/c-met signalling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. 101, 4477-4482
123. Borowiak, M., Garratt, A. N., Wustefeld, T., Strehle, M., Trautwein, C., and Birchmeier, C. (2004) Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. U. S. A. 101, 10608-10613
124. Fan, S., Wang, J. A., Yuan, R. Q., Rockwell, S., Andres, J., Zlatapolskiy, A., Goldberg, I. D., and Rosen, E. M. (1998) Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DAN-damaging agents. Oncogene 17, 131-141